Financhill
Sell
39

BBIO Quote, Financials, Valuation and Earnings

Last price:
$26.49
Seasonality move :
-20.12%
Day range:
$26.02 - $26.90
52-week range:
$21.62 - $44.32
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
22.18x
P/B ratio:
--
Volume:
4M
Avg. volume:
2.5M
1-year change:
-30.64%
Market cap:
$5B
Revenue:
$9.3M
EPS (TTM):
-$2.41

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BBIO
BridgeBio Pharma
$3.4M -$0.86 2390.78% -3.13% $48.56
ALNY
Alnylam Pharmaceuticals
$527M -$0.39 31.49% -80.37% $299.11
PFE
Pfizer
$14.9B $0.61 27.51% 12.4% $31.86
REGN
Regeneron Pharmaceuticals
$3.7B $11.70 9.55% 7.9% $1,053.08
SAVA
Cassava Sciences
-- -$0.88 -- -28% --
VRTX
Vertex Pharmaceuticals
$2.7B $4.13 10.59% 10.32% $498.37
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BBIO
BridgeBio Pharma
$26.50 $48.56 $5B -- $0.00 0% 22.18x
ALNY
Alnylam Pharmaceuticals
$245.50 $299.11 $31.7B -- $0.00 0% 14.86x
PFE
Pfizer
$26.36 $31.86 $149.4B 35.62x $0.42 6.37% 2.52x
REGN
Regeneron Pharmaceuticals
$701.85 $1,053.08 $77.1B 17.37x $0.00 0% 5.83x
SAVA
Cassava Sciences
$2.36 -- $113.5M -- $0.00 0% 2.59x
VRTX
Vertex Pharmaceuticals
$397.27 $498.37 $102.3B 25.59x $0.00 0% 9.73x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BBIO
BridgeBio Pharma
351.32% 3.297 35.65% 1.92x
ALNY
Alnylam Pharmaceuticals
96.94% 1.065 2.89% 2.57x
PFE
Pfizer
41.92% 0.516 40.56% 0.64x
REGN
Regeneron Pharmaceuticals
6.34% 1.460 1.71% 4.34x
SAVA
Cassava Sciences
-- -5.281 -- --
VRTX
Vertex Pharmaceuticals
-- 0.893 -- 2.08x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BBIO
BridgeBio Pharma
$2.1M -$187.1M -80.46% -- -5168.12% -$182.3M
ALNY
Alnylam Pharmaceuticals
$415M -$76.9M -36.66% -- -14.83% $39.5M
PFE
Pfizer
$12.4B $5.3B 2.66% 4.63% 31.06% $6.1B
REGN
Regeneron Pharmaceuticals
$3.2B $1.2B 16.02% 17.19% 40.5% $1B
SAVA
Cassava Sciences
-- -$30.6M -- -- -- -$18.3M
VRTX
Vertex Pharmaceuticals
$2.4B $1.1B -2.89% -2.89% 44.43% $1.3B

BridgeBio Pharma vs. Competitors

  • Which has Higher Returns BBIO or ALNY?

    Alnylam Pharmaceuticals has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of -22.27%. BridgeBio Pharma's return on equity of -- beat Alnylam Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BBIO
    BridgeBio Pharma
    78.11% -$0.86 $500.9M
    ALNY
    Alnylam Pharmaceuticals
    82.85% -$0.87 $1.1B
  • What do Analysts Say About BBIO or ALNY?

    BridgeBio Pharma has a consensus price target of $48.56, signalling upside risk potential of 83.28%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $299.11 which suggests that it could grow by 21.84%. Given that BridgeBio Pharma has higher upside potential than Alnylam Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBIO
    BridgeBio Pharma
    9 2 0
    ALNY
    Alnylam Pharmaceuticals
    11 8 1
  • Is BBIO or ALNY More Risky?

    BridgeBio Pharma has a beta of 1.079, which suggesting that the stock is 7.928% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.319, suggesting its less volatile than the S&P 500 by 68.077%.

  • Which is a Better Dividend Stock BBIO or ALNY?

    BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BBIO or ALNY?

    BridgeBio Pharma quarterly revenues are $2.7M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $500.9M. BridgeBio Pharma's net income of -$162M is lower than Alnylam Pharmaceuticals's net income of -$111.6M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 22.18x versus 14.86x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBIO
    BridgeBio Pharma
    22.18x -- $2.7M -$162M
    ALNY
    Alnylam Pharmaceuticals
    14.86x -- $500.9M -$111.6M
  • Which has Higher Returns BBIO or PFE?

    Pfizer has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of 25.23%. BridgeBio Pharma's return on equity of -- beat Pfizer's return on equity of 4.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    BBIO
    BridgeBio Pharma
    78.11% -$0.86 $500.9M
    PFE
    Pfizer
    70.27% $0.78 $159.2B
  • What do Analysts Say About BBIO or PFE?

    BridgeBio Pharma has a consensus price target of $48.56, signalling upside risk potential of 83.28%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 20.88%. Given that BridgeBio Pharma has higher upside potential than Pfizer, analysts believe BridgeBio Pharma is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBIO
    BridgeBio Pharma
    9 2 0
    PFE
    Pfizer
    8 13 1
  • Is BBIO or PFE More Risky?

    BridgeBio Pharma has a beta of 1.079, which suggesting that the stock is 7.928% more volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

  • Which is a Better Dividend Stock BBIO or PFE?

    BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.37% to investors and pays a quarterly dividend of $0.42 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

  • Which has Better Financial Ratios BBIO or PFE?

    BridgeBio Pharma quarterly revenues are $2.7M, which are smaller than Pfizer quarterly revenues of $17.7B. BridgeBio Pharma's net income of -$162M is lower than Pfizer's net income of $4.5B. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Pfizer's PE ratio is 35.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 22.18x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBIO
    BridgeBio Pharma
    22.18x -- $2.7M -$162M
    PFE
    Pfizer
    2.52x 35.62x $17.7B $4.5B
  • Which has Higher Returns BBIO or REGN?

    Regeneron Pharmaceuticals has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of 36.03%. BridgeBio Pharma's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 17.19%.

    Company Gross Margin Earnings Per Share Invested Capital
    BBIO
    BridgeBio Pharma
    78.11% -$0.86 $500.9M
    REGN
    Regeneron Pharmaceuticals
    86.8% $11.54 $31.3B
  • What do Analysts Say About BBIO or REGN?

    BridgeBio Pharma has a consensus price target of $48.56, signalling upside risk potential of 83.28%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 50.04%. Given that BridgeBio Pharma has higher upside potential than Regeneron Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Regeneron Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBIO
    BridgeBio Pharma
    9 2 0
    REGN
    Regeneron Pharmaceuticals
    12 6 0
  • Is BBIO or REGN More Risky?

    BridgeBio Pharma has a beta of 1.079, which suggesting that the stock is 7.928% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

  • Which is a Better Dividend Stock BBIO or REGN?

    BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BBIO or REGN?

    BridgeBio Pharma quarterly revenues are $2.7M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. BridgeBio Pharma's net income of -$162M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 22.18x versus 5.83x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBIO
    BridgeBio Pharma
    22.18x -- $2.7M -$162M
    REGN
    Regeneron Pharmaceuticals
    5.83x 17.37x $3.7B $1.3B
  • Which has Higher Returns BBIO or SAVA?

    Cassava Sciences has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of --. BridgeBio Pharma's return on equity of -- beat Cassava Sciences's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BBIO
    BridgeBio Pharma
    78.11% -$0.86 $500.9M
    SAVA
    Cassava Sciences
    -- -$0.58 --
  • What do Analysts Say About BBIO or SAVA?

    BridgeBio Pharma has a consensus price target of $48.56, signalling upside risk potential of 83.28%. On the other hand Cassava Sciences has an analysts' consensus of -- which suggests that it could grow by 4815.25%. Given that Cassava Sciences has higher upside potential than BridgeBio Pharma, analysts believe Cassava Sciences is more attractive than BridgeBio Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBIO
    BridgeBio Pharma
    9 2 0
    SAVA
    Cassava Sciences
    0 0 0
  • Is BBIO or SAVA More Risky?

    BridgeBio Pharma has a beta of 1.079, which suggesting that the stock is 7.928% more volatile than S&P 500. In comparison Cassava Sciences has a beta of -0.856, suggesting its less volatile than the S&P 500 by 185.551%.

  • Which is a Better Dividend Stock BBIO or SAVA?

    BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Cassava Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BBIO or SAVA?

    BridgeBio Pharma quarterly revenues are $2.7M, which are larger than Cassava Sciences quarterly revenues of --. BridgeBio Pharma's net income of -$162M is lower than Cassava Sciences's net income of -$27.9M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Cassava Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 22.18x versus 2.59x for Cassava Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBIO
    BridgeBio Pharma
    22.18x -- $2.7M -$162M
    SAVA
    Cassava Sciences
    2.59x -- -- -$27.9M
  • Which has Higher Returns BBIO or VRTX?

    Vertex Pharmaceuticals has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of 37.71%. BridgeBio Pharma's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -2.89%.

    Company Gross Margin Earnings Per Share Invested Capital
    BBIO
    BridgeBio Pharma
    78.11% -$0.86 $500.9M
    VRTX
    Vertex Pharmaceuticals
    85.84% $4.01 $15.6B
  • What do Analysts Say About BBIO or VRTX?

    BridgeBio Pharma has a consensus price target of $48.56, signalling upside risk potential of 83.28%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $498.37 which suggests that it could grow by 25.42%. Given that BridgeBio Pharma has higher upside potential than Vertex Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBIO
    BridgeBio Pharma
    9 2 0
    VRTX
    Vertex Pharmaceuticals
    17 12 2
  • Is BBIO or VRTX More Risky?

    BridgeBio Pharma has a beta of 1.079, which suggesting that the stock is 7.928% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

  • Which is a Better Dividend Stock BBIO or VRTX?

    BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BBIO or VRTX?

    BridgeBio Pharma quarterly revenues are $2.7M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. BridgeBio Pharma's net income of -$162M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 22.18x versus 9.73x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBIO
    BridgeBio Pharma
    22.18x -- $2.7M -$162M
    VRTX
    Vertex Pharmaceuticals
    9.73x 25.59x $2.8B $1B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 21

Quantum [QMCO] is up 26.28% over the past day.

Sell
46
NUKK alert for Dec 21

Nukkleus [NUKK] is down 22.94% over the past day.

Sell
1
IIPR alert for Dec 21

Innovative Industrial Properties [IIPR] is down 22.7% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock